What Гипотиазид Treats: Main Uses and Benefits

Гипотиазид (Hydrochlorothiazide) is considered relevant in addressing conditions marked by systemic volume imbalance and elevated blood pressure. The medication is commonly used to help manage chronic, high-risk conditions, which provides supportive relief over time. The therapeutic relevance of this medication is generally focused on providing sustained, long-term management of essential hypertension and is applied in addressing the symptom load of edema (fluid retention) in conditions like congestive heart failure and hepatic cirrhosis; it may be part of symptomatic management in patients with a risk of calcium-containing kidney stones. These applications represent the primary clinical uses of the medication.

This means that the medication supports patients coping with symptoms related to systemic imbalance, such as noticeable swelling in the feet and ankles, and is used for managing high blood pressure.

“The consistent management of volume and pressure may assist with reducing the long-term burden associated with cardiovascular events and chronic fluid accumulation.”

In clinical scenarios, it is applied in clinical settings that involve supportive symptom management where symptoms create noticeable functional strain.

Quick Fact: Relief for Swelling and Pressure
Primary Therapeutic Goal	Sustained reduction of volume and arterial pressure.
Symptom Focus	Managing fluid-induced swelling and systemic hypertension.
Patient Benefit	Supports a reduction in long-term cardiovascular burden and contributes to improved day-to-day comfort during symptomatic periods.

Regulatory References

1. NIH MedlinePlus overview

The eligibility for using Гипотиазид (Hydrochlorothiazide) is strictly defined by regulatory documents, which establish specific exclusions and conditional use populations.

Absolute Contraindications

Use of this medicine is absolutely prohibited for patients with:

• Anuria (absence of urine production).
• Known hypersensitivity to Hydrochlorothiazide or other sulfonamide-derived drugs.

---

Population-Specific Restrictions

Category	Regulatory Status	Status Context
Severe Renal Impairment	Not recommended	Ineffective for creatinine clearance < 30 mL/min and may cause drug accumulation.
Hepatic Impairment	Use with caution	Risk of electrolyte imbalance precipitating hepatic coma in severe liver disease.
Pregnancy	Not recommended	Routine use is inappropriate; generally avoided, except when clearly necessary.
Lactation	Not recommended	Excreted into breast milk; decision must be made to discontinue nursing or the drug.
Pediatric Use	Established use is limited	Safety is not established across all pediatric age groups; generally used with caution in children over 2 years.

Interaction Map: Interactions with other medicines and products — official regulatory information for Гипотиазид (Hydrochlorothiazide)

Interaction Scope

Property	Description
Medicinal product categories with documented interactions	Other Antihypertensive Agents; Corticosteroids and ACTH; Antidiabetic Drugs; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Anionic Exchange Resins.
Specific interacting medicines (if explicitly listed)	Lithium; Aliskiren; Cholestyramine Resins; Colestipol Resins.
Mechanistic basis of interactions (only if stated in label)	Reduction of renal clearance (for Lithium); Impairment of absorption (for Anionic Exchange Resins); Pharmacodynamic potentiation.
Timing-based interaction rules (if applicable)	Cholestyramine / Colestipol Resins require HCTZ administration 1 hour before or 4 to 6 hours after the resin.
Population-specific interaction notes (if applicable)	The combination with Aliskiren is contraindicated in patients with diabetes. Increased risk of renal impairment with NSAIDs/ACEI/ARB combination in patients with impaired renal function.
Interaction-related restrictions	Formally contraindicated combination with Aliskiren under specific conditions (diabetes).

---

Interaction Classifications (High-Level)

Property	Description
Interaction severity classification (as defined in official documents)	Contraindicated (Aliskiren in diabetes); Use with Caution / Clinical Significance (Lithium, NSAIDs, Antidiabetics, Resins).
Regulatory basis (EMA / FDA / etc.)	US FDA Prescribing Information / NIH DailyMed.
Interaction-context constraints (as defined in official documents)	Interactions often linked to additive effects on blood pressure reduction or electrolyte imbalances, or constraints due to absorption interference.

---

Resulting Interaction Structure

Official interaction statements:

• The co-administration of Aliskiren is contraindicated in patients with diabetes.
• Lithium clearance is reduced by HCTZ, which significantly increases the risk of lithium toxicity.
• Cholestyramine and Colestipol Resins reduce HCTZ absorption; administration must be separated by time.
• NSAIDs may reduce the diuretic and antihypertensive effects of HCTZ, and co-use in some patients increases the risk of renal impairment.
• Corticosteroids and ACTH intensify the risk of hypokalemia (electrolyte depletion).
• Alcohol, Barbiturates, and Narcotics may potentiate orthostatic hypotension.
• Antidiabetic Drugs may require dosage adjustment due to the potential for HCTZ to elevate blood glucose.

Connection to the overall interaction profile (2–4 sentences):

The regulatory documentation defines the product's interaction structure based primarily on pharmacodynamic reinforcement concerning blood pressure and electrolyte balance, and pharmacokinetic interference involving the reduced absorption of HCTZ by resins and the reduced renal clearance of co-administered drugs like Lithium. This structure includes a formal prohibition for a specific drug combination under a population-specific condition (Aliskiren in diabetic patients) and mandatory timing rules for co-administered resins. The documented statements establish the constraints on co-administration with other hypotensive agents and substances that affect fluid or electrolyte balance.

Blocking Salt and Water Reabsorption in the Kidney

Гипотиазид (Hydrochlorothiazide) works primarily by acting as a competitive inhibitor of the Sodium-Chloride Cotransporter (NCC) , a protein located in the distal convoluted tubules of the kidney. This molecular blockade prevents the reabsorption of Na^+ and Cl^- back into the body, initiating the process of saluresis and diuresis. This acute mechanism increases the excretion of salt and water, which in turn reduces the body's overall fluid volume and plasma volume.

Gradual Reduction of Peripheral Vascular Resistance

The long-term physiological effect is achieved via a separate mechanism: the modulation of vascular tone. Sustained sodium depletion from the body's tissues results in a lower sodium concentration within the walls of small arterioles. This change decreases the reactivity of the vascular smooth muscle to hormones that cause constriction (like Angiotensin II), which reduces Total Peripheral Resistance (TPR). This gradual lowering of resistance is the principal mechanism responsible for the sustained physiological change in circulatory resistance.

Administration Protocol for Hydrochlorothiazide

Hydrochlorothiazide (Гипотиазид) is typically administered via the oral route, appearing as a tablet, capsule, or a reconstituted oral suspension. The specific usage patterns are standardized based on dose, frequency, and patient context.

Dosing and Frequency

For the management of hypertension in adults, the usual starting dose is 12.5 mg to 25 mg taken once daily. The dose may be increased up to 50 mg daily, though doses exceeding this amount are generally not required for hypertension management. For edema, the adult daily dose is typically 25 mg to 100 mg, which may be taken as a single dose or divided into two doses. Intermittent therapy, such as administration on alternate days, is also an established schedule for edema management to reduce the potential for electrolyte disturbances.

Administration Conditions and Timing

Administration is advised in the morning to prevent interference with sleep caused by increased urination (nocturia). If two doses are required daily, the second dose should generally be taken before 6 PM. The medication may be taken with or without food.

Population-Specific Constraints

Dosing for pediatric patients is determined on a weight-based regimen (e.g., 1 mg to 2 mg/kg per day) and must not exceed specified maximum daily limits based on age. Furthermore, use is generally not recommended in patients who have severe renal impairment, as the medication is considered ineffective when creatinine clearance is below 30 mL/min. If a dose is missed, it should be skipped if the next dose is almost due; a double dose must not be taken.

Research Evidence / Overview of Studies for Гипотиазид

Evidence for Use in Managing Essential Hypertension

Research examining the use of Гипотиазид, or hydrochlorothiazide (HCTZ), primarily involves large-scale randomized controlled trials (RCTs) and various meta-analyses. These studies explored the research context involving high blood pressure, both when used alone and as part of combination therapies. Researchers monitored how the medication affects key measurements like systolic and diastolic blood pressure in various adult and older adult populations.

Findings from this research base describe patterns related to measured outcomes, such as blood pressure readings reported during the study periods. Furthermore, research explored and reported the incidence of certain long-term outcomes monitored in the observed populations. What remains uncertain is how the findings on long-term cardiovascular event rates compare when research evaluates this specific agent against certain other newer or longer-acting thiazide-like diuretics. Results for these comparisons were mixed across different studies.

Evidence for Use in Managing Edema (Fluid Retention)

The initial clinical evaluation and ongoing observational studies have explored the drug's use in conditions involving symptomatic fluid accumulation, or edema. Research monitored outcomes related to physical discomfort and systemic imbalance by measuring outcomes related to swelling and changes in overall fluid volume. Early regulatory trials and clinical documentation described that the medication was associated with changes in salt and water excretion.

Evidence for Use in Preventing Calcium-Containing Kidney Stones

Smaller clinical trials and observational studies have been applied in research contexts involving patients with a history of forming calcium-containing kidney stones. Research examined the medicine's effect on a physiological marker: the amount of calcium excreted in the urine. These studies also explored outcomes related to episodic changes by observing and monitoring the recurrence rate of kidney stones over defined time intervals.

Research Gaps and Areas of Uncertainty

There is limited information for long-term outcomes when comparing Гипотиазид to other, similar medications that are also used to treat high blood pressure, with some subgroup findings being uncertain. The volume of rigorous comparative evidence is smaller in areas like kidney stone research compared to the research base for hypertension. Research is ongoing in these areas.

Key Studies & References Chlorthalidone vs. Hydrochlorothiazide for Hypertension–Cardiovascular Events (DCP Trial)

Common questions about Гипотиазид (FAQ)

Q: What is Гипотиазид used for?

A: Гипотиазид, which contains the active ingredient Hydrochlorothiazide, is a type of medication known as a thiazide diuretic (or 'water pill'). It is indicated for treating high blood pressure (hypertension), either alone or in combination with other medications. It is also used to manage edema (fluid retention) associated with conditions such as heart failure, liver cirrhosis, or kidney disorders.

Q: How does Гипотиазид work in the body?

A: Гипотиазид works by acting on the kidneys to increase the removal of salt and water from the body through urine. This process helps to reduce the volume of fluid in the body and can contribute to lowering blood pressure.

Q: What are the most common side effects associated with Гипотиазид?

A: The most commonly reported side effects may include:

• Electrolyte imbalances, such as low potassium (hypokalemia) or low sodium (hyponatremia).
• Dizziness or lightheadedness, particularly when rising from a sitting or lying position.
• Increased blood sugar levels.
• Increased uric acid levels, which could potentially trigger gout in susceptible individuals.
• Consulting the official product information for a complete list of potential side effects is recommended.

Q: Is it necessary to monitor anything while taking this medication?

A: Due to the potential for electrolyte changes, your healthcare provider will likely schedule regular blood tests to monitor the levels of potassium, sodium, and other electrolytes, as well as kidney function, especially during the start of treatment or following a dosage adjustment. Blood pressure should also be monitored regularly.

Q: What should I do if I forget to take a dose?

A: If a dose is missed, it is generally advised to take the missed dose as soon as you remember, unless it is close to the time for your next scheduled dose. If it is almost time for the next dose, it is typically recommended to skip the missed dose and resume your regular schedule. Do not take a double dose to make up for the one you missed. Always follow the specific advice provided by your prescribing healthcare professional.

Q: Are there any foods, drinks, or medications to avoid while taking Гипотиазид?

A: It is important to discuss all medications and supplements you use with your healthcare provider to check for potential interactions. Known interactions include:

• Lithium preparations, as this medication may increase lithium levels.
• Certain nonsteroidal anti-inflammatory drugs (NSAIDs).
• Alcohol may increase the risk of dizziness or lightheadedness.
• Due to the risk of potassium loss, your doctor may recommend dietary changes or a potassium supplement. Always consult your physician or pharmacist before starting any new medication, supplement, or making significant dietary changes.

Official Storage and Disposal Requirements

Hydrochlorothiazide (Гипотиазид) must be stored strictly according to regulatory labeling to maintain its stability and effectiveness. The medication should be kept at room temperature in the tightly closed container in which it was dispensed. Protection is required from environmental factors, meaning it must be stored away from excess heat and excess moisture; storage in the bathroom is specifically prohibited. Liquid formulations and capsules must not be allowed to freeze.

For household safety, the medication must be kept securely out of the reach and sight of children, ideally in a safe, locked location, and safety caps must always be locked. Regarding disposal, unused or expired medication should be handled according to specific local environmental guidelines, which can typically be obtained from official government drug disposal resources.